Sarah Cannon Research Institute | Strategic Alliance Partners

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at more than 200 locations in 20+ states across the U.S. Learn more about our research offerings.

Connect with us:

Latest from Sarah Cannon Research Institute

Dr. Donnellan Reflects on FDA Approvals in Acute Leukemia

March 02, 2018

Video

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, reflects on some of the most pivotal FDA approvals in acute leukemia in the past year.

Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC

March 02, 2018

Article

David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.

Myeloma Expert Provides Insight on Practice-Changing Data

March 02, 2018

Article

Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.

Efforts Continue to Enhance Stem Cell Transplants

March 01, 2018

Article

Carlos R. Bachier, MD, discusses the evolution of stem cell transplantation as a treatment for patients with hematologic malignancies.

Expert Highlights Developments in Myeloid Malignancies

February 27, 2018

Article

Suman Kambhampati, MD, discusses available treatments for MDS and ongoing clinical trials investigating targeted treatments in myeloid malignancies.

Flinn Highlights Emerging Combinations in CLL

February 26, 2018

Article

Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.

Berdeja Looks Ahead in Multiple Myeloma Treatment

February 26, 2018

Article

Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.

Dr. Berdeja Discusses the Future of Treatment for Myeloma

February 24, 2018

Video

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

Dr. Bachier on the Evolution of Stem Cell Transplants in Hematologic Malignancies

February 24, 2018

Video

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses the advancement of supportive care in hematologic malignancies.

Dr. Kambhampati on Venetoclax in Patients With Myeloid Malignancies

February 23, 2018

Video

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Cancer Institute, discusses the impact of single-agent venetoclax (Venclexta) in patients with myeloid malignancies.

Dr. Donnellan on Developing Combinations in AML

February 23, 2018

Video

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations in light of newly FDA-approved agents in acute myeloid leukemia (AML).

Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLL

February 14, 2018

Video

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121

February 03, 2018

Video

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Myeloma

January 30, 2018

Article

Jesus Berdeja, MD, discusses ongoing research with bb2121 in patients with relapsed/refractory myeloma.

Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL

January 06, 2018

Video

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy

January 03, 2018

Video

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.

Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast Cancer

December 21, 2017

Video

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

Dr. Bendell Discusses Pembrolizumab in CRC

December 19, 2017

Video

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

November 28, 2017

Video

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

Dr. Hamilton Discusses Tucatinib in HER2+ Breast Cancer

October 24, 2017

Video

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.